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A B S T R A C T   
Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially fatal and frequently undiagnosed 
form of pulmonary hypertension (PH), classified within group 4 by the World Health Organization (WHO). It is a 
type of precapillary PH, which uncommonly develops as a peculiar sequel of acute pulmonary embolism due to 
the partial resolution of the mechanically obstructing thrombus with a coexisting inflammatory response from 
pulmonary vessels. CTEPH is one of the potentially treatable forms of PH whose current standard of care is 
surgical pulmonary endarterectomy. Medical therapy with few drugs in non-operable disease is approved and has 
shown improvement in patients’ hemodynamic condition and functional ability. Recently, balloon pulmonary 
angioplasty (BPA) has shown promising results as a treatment option for technically inoperable patients, those 
with unacceptable risk-to-benefit ratio and in a case of residual PH after endarterectomy. Lack of meticulous 
CTEPH screening programs in post-pulmonary embolism patients leading to underdiagnosis of this condition, 
complex operability assessment, and diversity in BPA techniques among different institutions are still the issues 
that need to be addressed. In this paper, we review the recent achievements in the management of non-operable 
CTEPH, their outcome and safety, based on available data.   
1. Introduction 
Chronic thromboembolic pulmonary hypertension (CTEPH) is a 
subtype of pulmonary hypertension (PH) recognized as a separate entity 
within pulmonary arterial hypertension (PAH). CTEPH is a rare and 
potentially fatal complication of pulmonary embolism (PE) with a spe-
cific physiopathology and represents at least 19 % of patients with PH 
according to various registries [1–4]. The estimated overall annual 
incidence of CTEPH is 3–5 patients per 100,000 inhabitants [5]. Its 
frequency after pulmonary embolism has been shown in recent studies 
to vary between 0.4–3 % [6,7]. If untreated, long-term outcomes are 
relatively poor; 5-year survival rate of 30 % for those with a mean 
pulmonary arterial pressure (mPAP) > 40 mmHg and 10 % for those 
with mPAP > 50 mmHg [8,9]. Currently, pulmonary endarterectomy 
(PEA) is the treatment of choice with an in-hospital mortality rate of 2.2 
% for all eligible CTEPH patients at experienced centers [10]. PEA can 
potentially cure CTEPH disease, especially in cases with organized 
thrombi of the proximal branches of pulmonary arteries [11]. However, 
patient selection for PEA is a complex process, and based on a multi-
disciplinary team decision. Eligible patient rates vary wildly, even in 
expert centers with high volumes, ranging from 39 % to 88 % in recent 
reports [12]. 
Advances in medical therapy promote adjunctive drugs in CTEPH 
patients, especially for those with no surgical option or those with re-
sidual PH after PEA. To date, Riociguat, Macitentan, and subcutaneous 
Treprostinil are the only drugs proven by randomized control trials to be 
capable of improving the exercise capacity (6-min walking distance) of 
CTEPH patients [13–15]. The added value of targeted medical therapy – 
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as well as the appropriateness of routine use – is still a matter of debate 
and calls for further trials and long-term outcome data [16,17]. 
Percutaneous balloon angioplasty is a minimally invasive technique 
routinely used as primary treatment for obstructive vascular disease in 
many conditions [18]. The first report of doing balloon pulmonary an-
gioplasty (BPA) to treat CTEPH in a patient ineligible for PEA was 
published more than three decades ago [19]. In 2001, the first case series 
of BPA reported significant improvement of New York Heart Association 
class and 6-minute walking distance (6MWD) in 18 patients [20]. 
However, the high procedural and post-procedural complication rate 
(61 %) was discouraging for further studies. From then on, BPA had been 
particularly investigated and advanced in Japanese studies, which re-
ported promising results in improving patients’ hemodynamics, right 
ventricular (RV) systolic and diastolic function, respiratory and exercise 
capacity, and quality of life with fewer complications [21–23]. During 
the last few years, BPA refinement and development continued with 
improved outcome and safety data and currently carries a class IIb 
recommendation to treat inoperable CTEPH in the most recent European 
guidelines [24]. 
This manuscript reviews the diagnostic pathway of CTEPH and the 
various treatment options, especially the newer non-surgical strategies. 
The required knowledge to introduce a BPA program will be discussed, 
with a particular focus on patient selection and specificities of BPA for 
CTEPH patients. 
2. CTEPH definition and physiopathology 
PH was defined by European guidelines as a resting mPAP equal to or 
higher than 25 mmHg [24] and more recently by the 6th World Sym-
posium on Pulmonary Hypertension as mPAP > 20 mmHg and pulmo-
nary vascular resistance (PVR) ≥ 3 WU. CTEPH is a precapillary type of 
PH characterized by normal pulmonary artery wedge pressure ≤ 15 
mmHg during resting right heart catheterization (RHC) and chronic 
thromboembolic evidence shown as mismatched perfusion defects in 
pulmonary arteries on computed tomographic pulmonary angiography 
(CTPA), lung perfusion scintigraphy or pulmonary angiography [25]. It 
is a rare, progressive pulmonary vascular disease that is usually the 
consequence of prior acute PE, with persistent obstruction of large to 
middle-sized arteries by organized thrombi. Fibrinolytic disorders, un-
derlying hematological or autoimmune conditions, inflammation, and 
even infection likely play a substantial role [26,27]. Non-resolving PEs 
undergo firbrinotic transformation and cause partial or complete 
obstruction of large and middle-sized vessels, but micro-vessel diesase 
characterized by intimal proliferation and increased media thickness, 
often referred to as "microvascular remodelling", is now recognized as a 
contributing factor to PH in CTEPH [28]. However, the underlying 
mechanisms are not fully understood, and growing evidence indicates 
that small-vessel disease in obstructed territories is key to hemodynamic 
compromise, functional impairment, and disease progression, perhaps 
due to excessive collateral high-pressure systemic blood supply and 
increased shear stress [29]. 
Patients with CTEPH usually present with non-specific symptoms 
such as progressive dyspnea and exercise intolerance [12]. In more 
advanced disease, additional symptoms and signs related to RV 
dysfunction may be prominent, such as peripheral edema, exertional 
chest pain, or syncope. History of acute venous thromboembolic events 
before the onset of dyspnea may be absent in as many as 38 % of patients 
with surgically accessible disease. This should not dissuade from 
thinking about the diagnosis of CTEPH in patients with unexplained 
dyspnea [30], especially since post-PE screening programs are not 
usually recommended and implemented [31]. Clinical symptoms and, in 
particular non-resolving dyspnea, remain the main factor leading to 
suspicion and treatment of CTEPH [32]. Whenever PH is suspected, the 
distinction between CTEPH and other entities is crucial because CTEPH 
is the only entity potentially amenable to PEA or BPA. 
3. CTEPH imaging and classification 
Several imaging modalities find their place in the workup of sus-
pected CTEPH (Fig. 1). Transthoracic echocardiography is a simple and 
effective means of assessing the right heart chambers and the probability 
of PH. RV hypertrophy (wall thickness >5 mm) and RV dilation are 
indicative of chronic RV loading and adaptive remodeling, and echo-
cardiography can suggest elevated PVR before RHC [33]. According to 
the latest diagnostic algorithm from the European Society of Cardiology 
(ESC) [24], patients with intermediate or high probability of PH at 
echocardiography benefit from radionuclide ventilation-perfusion 
(V/Q) lung scintigraphy, which accurately detects suggestive abnor-
malities, typically large mismatched perfusion defects. Sensitivity and 
specificity are excellent (>90 %) with both planar V/Q, and V/Q 
single-photon computed tomography (SPECT) [34]. Additionally, due to 
its nearly perfect negative predictive value, V/Q can safely exclude 
CTEPH and avoid unnecessary additional diagnostic tests. On the other 
hand, in the presence of mismatched perfusion abnormalities, further 
diagnostic tests are required because of the limited specificity of V/Q 
scintigraphy. 
CT pulmonary angiography has established itself as the principal 
non-invasive instrument to assess the pulmonary vasculature, with the 
ability to evaluate the pulmonary anatomy and cardiac morphology at 
the same time [35,36]. While the sensitivity of V/Q was long considered 
higher than that of CTPA for the detection of CTEPH, recent data show 
equivalent sensitivities for these two imaging tests, which has been 
attributed to technological improvements [3,37]. The sensitivity and 
specificity of CTPA to detect CTEPH findings are excellent at the main 
and lobar arterial segments (97.0 % and 97.1 %, respectively) and 
slightly lower at the segmental and subsegmental levels (85.8 % and 
94.6 %) [38]. Besides the detection of typical CTEPH signs including 
increased right-to-left ventricular ratio, dilated main pulmonary artery, 
organized chronic emboli, peripheral tapering of pulmonary arteries, 
systemic collaterals, and mosaic attenuation pattern, CTPA has the po-
tential to unveil alternative diagnoses (mimickers of CTEPH) such as 
systemic vasculitis, arterial sarcoma, fibrosing mediastinitis, or pulmo-
nary veno-occlusive disease [39,40]. More recently, dual-energy CT 
systems have become available for clinical use, opening the door to a 
new era of combined morphological and functional vascular assessment. 
Dual-energy CT (Figs. 2,3 and 5) platforms acquire spectral X-ray 
attenuation data without additional radiation or iodine dose [41] and 
allow semi-quantitative evaluation of pulmonary perfusion [42,43], as 
well as blood volume (Fig. 3, panel b). Whereas iodine density maps 
show promising initial results as a surrogate marker of pulmonary 
perfusion [44], further evaluation with prospective studies is warranted 
to establish this technology as a clinical standard [45]. 
Recently, pulmonary magnetic resonance imaging has gained inter-
est as a radiation-free alternative to other imaging techniques in CTEPH. 
It has limited spatial resolution compared to CTPA but offers the 
advantage of measuring cardiac and pulmonary hemodynamics. Draw-
backs include the required level of training and expertise to perform it 
properly and its time-consuming nature [46,47]. 
Right heart catheterization is the final diagnostic procedure that will 
confirm PH with invasive hemodynamic assessment and remains the 
gold standard to diagnose PH. Care must be taken in patients with 
normal resting mPAP (< 20 mmHg) but high clinical or radiological 
suspicion of CTEPH because abnormal mPAP may become apparent only 
during exercise. This condition is named Chronic Thrombo-Embolic 
Disease (CTED), and its management remains poorly defined. RHC is 
usually combined with catheter-based pulmonary angiography, which 
helps determine the distribution and extent of thromboembolic burden, 
especially at the subsegmental level. Diagnostic angiography remains a 
mainstay in evaluating surgical accessibility, and the development of 
BPA restores the importance of accurate mapping of occlusive target 
lesions with transcatheter angiography. Findings include vessel nar-
rowing (Fig. 4), webs and bands (Fig. 2), pouch defects, or occlusions 
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(Fig. 5). The latest proposed angiographic classification of pulmonary 
vascular lesions specifically tailored for BPA identifies five lesion types. 
Type A: ring-like stenosis lesion; type B: web lesion; type C: subtotal 
lesion; type D: total occlusion lesion; and type E: tortuous lesion [48]. 
The highest success rate and lowest complication rate of BPA were 
attributed to type A lesions followed by type B, while type D and E le-
sions had the least success rate, and the highest complication rate was 
noticed in type E lesions [49]. 
4. CTEPH management 
Table 1 presents a comparision of available treatment strategies. 
Early referral for evaluation of pulmonary thromboendarterectomy is 
the rule for all patients and should not be delayed even with only mild 
symptoms. All patients with CTEPH should receive treatment because 
they are likely to develop progressive disease and have a high risk of 
dying from right heart failure [50]. A mPAP exceeding 30 mmHg is 
predictive of pulmonary vascular impairment and poor prognosis [51, 
52]. Surgery involves deep hypothermic circulatory arrest and is the 
only definitive therapy for CTEPH. The decision to operate should be 
discussed in an expert center, primarily taking into account the four 
following parameters: the presence of hemodynamic and/or respiratory 
compromise; the surgical accessibility of the thrombi (main, lobar, or 
segmental arteries); the patient’s comorbidities; and the willingness of 
the patient. However, it should be noted that a disproportionately high 
PVR associated with a limited extent of arterial occlusive disease is 
suggestive of micro-vessel disease, and such patients are unlikely to 
benefit from PEA or BPA. Radiologists play a crucial role during the 
preoperative workup by mapping both the severity and distribution of 
thrombi, characterizing lesion appearance, and the vessels’ status 
downstream. Fig. 3 shows a patient who was successfully treated with 
surgery. When PEA is not feasible, BPA – as a minimally invasive 
catheter-based technique – represents an acceptable alternative. Medi-
cal treatment is not curative, and its effects are relatively modest. 
Initiation of lifelong anticoagulant therapy to prevent recurrent venous 
thromboembolism and in situ pulmonary artery thrombosis is manda-
tory [53], usually with antivitamin K with a target INR between 2.0 and 
3.0, but other options are currently available, including direct oral an-
ticoagulants’ (DOAC) administration. However, the latter have not been 
studied in detail for patients with CTEPH. 
5. The rationale for pulmonary arterial angioplasty 
Because lowering the pulmonary vascular resistance in CTEPH is 
critical, inoperable patients may benefit from endovascular treatment 
restoring blood flow in obstructed or stenotic arteries. The goal of BPA is 
to improve hemodynamics by increasing pulmonary perfusion and 
reducing RV afterload, eventually preventing RV failure. Over time, 
treatment with BPA induces RV reverse remodeling and improves sys-
tolic function [54]. In contrast to conventional angioplasty, BPA uses 
undersized balloons over guide wires, intending to relieve stenosis 
exclusively by breaking intraluminal webs and bands, without dissecting 
other vessel wall layers [48]. 
BPA should be offered to patients with inoperable CTEPH due to 
distal distribution of vascular obstructions; those with a poor risk-to- 
benefit ratio for surgery (e.g., few lesions but severe cardiac conse-
quences, significant comorbidities); those with recurrent or persistent 
PH after surgical PEA; patients necessitating rescue angioplasty after 
early failure of PEA [55]. Another indication can be refractoriness to 
medical therapy with contraindication to surgery. Because of technical 
Fig. 1. Recommended diagnostic algorithm for chronic thromboembolic pulmonary hypertension (CTEPH). Adapted from the 2019 ESC pulmonary embolism 
guidelines [90]. TTE: Trans thoracic echocardiography, PH: Pulmonary hypertension, CTEP: Cardiopulmonary exercise testing, V/Q: ventilation/perfusion, PH: 
pulmonary hypertension, CTPA: computed tomography pulmonary angiography. 
D.C. Rotzinger et al.                                                                                                                                                                                                                            
European Journal of Radiology 136 (2021) 109562
4
limitations, BPA should not be considered in total unilateral occlusion or 
large central clots [48]. 
6. Target groups, indications, contraindications 
Eligibility assessment is a challenging and multifactorial task 
requiring a multidisciplinary team of CTEPH experts whose members 
may vary depending on local practice. Core members may include PH 
pulmonologists, diagnostic cardiologists and radiologists, interventional 
radiologists/cardiologists. Including cardiothoracic surgeons is an 
attractive means of providing a balanced and thorough multidisci-
plinary discussion of tailored treatment. Depending on patients’ ability 
to receive general anesthesia, input from anesthesiologists can influence 
treatment decisions. Whenever a BPA program is started, a concomitant 
PEA track should be available and discussed in the multidisciplinary 
team since PEA remains the method of choice for eligible patients with 
CTEPH. Furthermore, due to the absence of systematic post-PE screening 
programs, PH management teams should closely collaborate with pul-
monary embolism response teams since most CTEPH patients are iden-
tified through acute PE referrals. Although consensus regarding PEA and 
BPA’s merits gradually develops, there may still be considerable vari-
ability in practice across institutions and nations. Patients who have the 
highest benefit from BPA are those with an unfavorable risk/benefit 
ratio for PEA, more distal location of obstructive thrombotic lesions, and 
Fig. 2. Dual-energy CT pulmonary angiography 
shows several webs in the left lower lobe’s 
anterior and lateral segmental arteries on axial 
(a) and coronal reformatted (b) images. Coronal 
reformatted iodine density map reveals 
impaired perfusion in the left lower lobe (c). 
Selective transcatheter pulmonary angiography 
shows incomplete opacification of the anterior 
segmental artery due to webs (d). Following 
treatment with balloon pulmonary angioplasty 
(e), a final angiogram shows the absence of 
stenosis (f).   
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persistent or recurrent PH after previous endarterectomy. Advanced age 
itself is not considered a contraindication for a BPA procedure; a small- 
sample study of aged CTEPH patients (median age of 81) demonstrated 
safe and efficacious outcomes [56]; evidently, elderly patients might 
carry a larger risk of periprocedural complications and mortality. As 
expected, Patients with poorer baseline hemodynamic status may have a 
higher complication risk. 
7. Technical considerations of pulmonary angioplasty 
Pulmonary angioplasty procedural approaches may vary between 
different centers. The usually practiced technique is as follows: typically, 
the procedure begins with a general or selective angiogram to determine 
the extent and distribution of thromboembolic lesions. In our practice, 
selective angiograms are guided by CTPA to save time and contrast 
media. A pre-shaped 6-French guiding catheter is introduced through a 
long 6, 7, or 8-French sheath inserted through the femoral or jugular 
vein, advanced to reach the pulmonary trunk, and guided to the right or 
left main pulmonary artery. In the next step, a 0.014 or 0.018-inch 
guidewire is used to cross the target lesion, and a balloon catheter of 
appropriate size is selected to dilate the vessel. Careful verification of 
proper guidewire placement is mandatory before balloon inflation. For 
initial treatments, undersized balloons are used, whereas larger balloons 
can be employed in subsequent sessions according to the reference 
vessel diameters provided by angiography. Generally, multipurpose 
type catheters are suitable for the right lung’s segmental arteries, 
whereas Amplatz type catheters are appropriate for segmental arteries of 
the left lung. The lobe exhibiting the least perfusion, as identified by 
lung perfusion scintigraphy, is commonly treated first. During the pro-
cedure, intravenous heparin is administered to target an activated 
clotting time of 200 s, and oxygen is supplemented to keep the satura-
tion level above 95 %. If the lesions being treated are located in the 
lower lobes, the patient is asked to hold his breath or inhale deeply to 
stretch the pulmonary arteries and help the guidewire reaching its 
target. Unlike PEA, BPA does not require general anesthesia. The best 
therapeutic result is obtained through multiple sessions of angioplasty 
3–7 days apart. Usually, 4–6 different BPA procedures per patient are 
necessary to achieve complete treatment. Initial experiences advocated 
limiting BPA to one major vessel (e.g., lobar or segmental) per session or 
two small vessels (e.g., subsegmental). We still apply these rules for the 
first session and in patients with a high baseline pressure (>40 mmHg). 
Because extensive reperfusion is expected to enhance BPA’s therapeutic 
effect, most interventionists recommend treating the most remarkable 
webs in the lower lobes first. Like many procedures, the fluoroscopy 
duration limit is 60 min per session. Periprocedural predictive factors of 
successful reperfusion, including venous return, are still debated and 
under evaluation. Furthermore, factors associated with post-reperfusion 
edema and the role of systemic supply are unknown. 
8. Evidence for pulmonary angioplasty 
Table 2 demonstrates the largest (including 50 patients or more) 
studies so far. The most extensive case series reported to now is a seven- 
center Japanese registry by Ogawa et al. of 1408 procedures for 308 
patients. Follow-up data from 196 patients revealed a significant 
reduction in mPAP from 43 to 24 mmHg after the final BPA session and 
22 mmHg at follow-up evaluation, accompanied by a significant decline 
in the necessity for concomitant oxygen and medical treatment. The 
overall complication rate was 36 %, and the three-year survival rate was 
94.5 % [57]. Aoki et al. also evaluated the long-term effect and outcome 
of pulmonary angioplasty in 84 inoperable CTEPH patients [58]. Results 
showed that BPA decreased the mPAP to almost normal levels (from 38 
to 25 mmHg) and led to significantly improved PVR, BNP levels, and 
accordingly 6MWD. Most notably, the plasma BNP levels, hemody-
namics amelioration and exercise capacity persisted during the 
long-term follow-up period (43 ± 27 months). For 77 patients who 
completed BPA treatment, the 5-year survival rate reached to 98.4 % 
[58]. 
A study assessed the outcome of inoperable CTEPH patients treated 
with BPA and those managed with PEA, and the results indicated similar 
safety and efficacy in both groups [59]. Of note, the mortality rates were 
3.4 % and 8.3 % in BPA and PEA patients, respectively. 
Another same-year study by Inami et al. compared the outcomes of 
medical and invasive (BPA or PEA) approaches as CTEPH patients 
therapy. While the interventional (BPA or PEA) group had a significantly 
worse baseline hemodynamic status, they had significantly higher 5- 
year survival rates than the medically-treated group (98 % versus 64 
%, respectively; p < 0.0001). Although in the interventional group the 
effect on total pulmonary resistance (TPR), 6MWD, and plasma BNP 
levels were similar for PEA and BPA, the surgical procedure resulted in a 
greater mPAP reduction [60]. Recently, Sumimoto et al. observed sub-
stantial RV reverse remodeling following BPA treatment in 45 CTEPH 
patients assessed with speckle-tracking echocardiography, as well as 
hemodynamic improvement [61], further supporting the use of BPA. Of 
note, the improvement of subjective symptoms and pulmonary hemo-
dynamics after BPA is not immediate, and a certain amount of time is 
needed before the maximal therapeutic effect is seen [21]. Recently, a 
study evaluated the Electrocardiographic (ECG) parameters associated 
with RV hypertrophy in 60 CTEPH patients before and after BPA pro-
cedures, which showed decreased mPAP and an improvement in ECG 
findings related to RV hypertrophy. By comparing ECGs and mPAP 
measurements, the authors found that amplitude decrease of the S and R 
waves (lead V6) and P wave (lead II) before and after BPA strongly 
correlated with mPAP decline. Also, at 6-month follow-up, a decrease in 
the R wave amplitude (V1 lead) and S wave (V5 lead) implied a better 
functional status [62]. 
Despite a substantial body of literature related to contemporary BPA 
practice, the available data is still limited, based on non-randomized 
Fig. 3. Dual-energy CT pulmonary angiography displayed as an iodine density overlay (a), and total pulmonary blood volume image (b). Extensive bilateral 
eccentric mural thrombosis of the central pulmonary arterial branches (a) with corresponding decreased lung perfusion areas (a and b) are seen. Post endarterectomy 
CT pulmonary angiography reveals patency of the branches (c); accompanying reperfusion edema of the left lower lobe is also noted. 
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series. No randomized-controlled trials comparing PEA with BPA 
currently exist, and consequently, BPA is mostly applied in patients 
deemed non-eligible for surgery or having recurrent PH after PEA. Ont 
the other hand, current research attempts to fill gaps in the literature 
related to BPA vs. medical therapy. First and foremost, the Riociguat 
Versus Balloon Pulmonary Angioplasty results in Non-operable Chronic 
ThromboEmbolic Pulmonary Hypertension (RACE) trial are eagerly 
awaited. In this trial, patients were randomized to receive either BPA or 
Riociguat, with a 26-week follow-up. According to preliminary data 
presented at the European Respiratory Society (ERS) 2019 conference 
[63], PVR was reduced by almost 60 % in the BPA arm versus 32 % in the 
Riociguat arm (p < 0.0001). While BPA appears to be more efficient than 
Riociguat, these results open the door to further research, including the 
investigation of combined therapy. This promising hybrid therapy could 
act as a "bridge" therapy before BPA to improve patients’ hemodynamic 
condition and potentially diminish post-procedural complication risks 
or be used after BPA in patients whose hemodynamic response is not 
satisfactory. While the combination has been successfully described 
[64], other reports of worsening of clinical and hemodynamic status 
[65] mandate the issue to be systematically evaluated. 
Secondly, the multicentre randomized controlled trial of balloon 
pulmonary angioplasty and Riociguat (MR BPA) trial [66] also ran-
domized inoperable CTEPH patients to receive either BPA or Riociguat, 
with a 12-month follow-up. It will hopefully shed more light on the 
Fig. 4. Chest CT in the lung window (a) and 
corresponding lung scintigraphy (b) showing 
bilateral perfusion defects sparing the left pos-
terior basal segment in a patient with a history 
of acute pulmonary embolism one year prior, 
and documented precapillary pulmonary hy-
pertension. One of multiple stenoses (c) at 
transcatheter angiography consistent with 
CTEPH. Balloon pulmonary angioplasty of the 
right posterior basal artery (d) and post- 
angioplasty angiogram shows substantial ste-
nosis reduction. Follow-up CT pulmonary angi-
ography in oblique maximum intensity 
projection (MIP) reformat persistent stenosis 
relief in the right posterior basal artery (white 
arrow) 2 years later.   
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appropriateness of endovascular treatment for CTEPH. 
9. Combined BPA-PEA, rescue BPA, and BPA application in non- 
hypertensive chronic thromboembolism conditions 
Wiedenroth et al. proposed combined BPA-PEA as a novel option for 
highly selected high-risk CTEPH patients with inoperable contralateral 
pulmonary artery obstructions. Candidates underwent BPA treatment on 
the inoperable lung in the middle of the rewarming phase of the car-
diopulmonary bypass [67]. 
There have been suggestions for "Rescue BPA" in a few case reports in 
terms of stabilization before PEA in patients with promptly worsening 
heart failure [68,69]. 
Chronic thromboembolic disease (CTED) contrasts from CTEPH by 
the absence of PH at rest. Curiously, a small study assessed BPA as a 
potential treatment for these patients, during which 35 BPA in-
terventions were performed in 10 consecutive CTED patients. Follow-up 
6 months after the last intervention showed improvement in the PVR, 
pulmonary arterial compliance, functional class and 6MWD [70]. 
10. Safety and complications of BPA 
Possible BPA procedure complications consist of pulmonary artery 
injury, which may directly or indirectly result in pulmonary edema 
Fig. 5. Dual-energy CT pulmonary angiography 
in the lung window (a) shows virtually indis-
cernible mosaic attenuation, much better 
depicted on the iodine density map (b) where 
perfusion defects in the right middle lobe, lin-
gula, and left inferior lateral segments are seen. 
A coronal maximum intensity projection (MIP) 
in the standard window (c) shows a sub-
segmental occlusion (white arrowhead), 
confirmed upon transcatheter angiography (d). 
Balloon pulmonary angioplasty (e) and subse-
quent selective angiography with restored 
parenchymal perfusion (f). Note that ideally, 
the wire guide (e) should cross the lesion and be 
straight in the vessel under treatment, which 
was not the case in this example where the oc-
clusion was too long to be crossed all at once. 
This is why the angioplasty was performed with 
suboptimal wire positioning.   
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(reperfusion lung edema), hemorrhage, pleural effusion, and pseudoa-
neurysm formation. Peri or post-procedure coughing or hemoptysis 
would be alarming signs. Radiation and contrast exposure to the oper-
ator and patient is another continuing concern with BPA. 
Inami et al. assorted Pulmonary Artery Injury (PAI) into wire 
perforation, high-pressure perfusion injury, pulmonary artery rupture, 
and pulmonary artery dissection [71]. The most frequent procedural 
arterial injury is wire perforation, which can be hampered by avoiding 
too deep insertion of guidewires into lesions without distal visibility and 
stabilizing the guiding catheter. These complications can be asymp-
tomatic or cause signs and symptoms such as coughing, hemoptysis, 
tachycardia, and increased PAP. High-pressure perfusion injury is 
mainly seen in patients with severe baseline pulmonary hypertension 
(mPAP > 50 mmHg), and is induced by sudden exposure of distal pul-
monary branches and tissue to the high proximal PAP following balloon 
dilation. Applying the proposed pressure-wire technique can assist in 
deterring this complication. The high-pressure injury may also follow 
forceful and/or rapid injection of contrast material preventable by 
gentle injection. Arterial rupture commonly occurs due to the use of 
inappropriately-selected balloons or overdilation of the stenotic point. 
Inami et al. also introduced a Pulmonary Edema Predictive Scoring 
Index (PEPSI) based on the total change in pulmonary flow grade and 
baseline pulmonary vascular resistance to predict the risk of reperfusion 
pulmonary edema [72]. Also, they evaluated the outcome for a combi-
nation of PEPSI and pressure-wire technique in a study [73]. Kurzyna 
et al. demonstrated that targeting bands, webs, and rings while avoiding 
total occlusions using smaller balloons and guidewires with soft tips 
significantly reduces the complication rate (hemoptysis and reperfusion 
injury) [74]. 
Once pulmonary artery injury occurred, timely and appropriate 
management is key. The recommended methods are vaso-occlusion 
using a metallic coil or bio-absorbable gelatin, stent-graft delivery, 
and prolonged balloon sealing [75]. In case of bleeding and high clotting 
time, slow protamine infusion may be initiated. As mentioned above, 
type A and B lesions have the lowest, while type E lesions have the 
highest complication rate. 
11. Local effects of pulmonary angioplasty 
Angiographically, treated stenoses may remain apparent immedi-
ately after BPA because the re-expansion of vessel diameter can evolve 
[76]. Pre-procedure and immediate post-procedure PVR, as well as 
NT-proBNP, are long-term predictors of procedure prognosis [77,78]. Of 
interest, a study showed hemodynamic improvement and PVR reduction 
Table 1 
Comparison of treatment strategies for chronic thromboembolic pulmonary 
hypertension (CTEPH).  



















failed to benefit 
from PEA  
Evidence Small RCTs 
Observational 













60 % reduction 
[>500] [21–,22, 
23,63] 









effect over 2 
years 
Limited data: 
85− 98% 5-year 
survival 
Limited data; 
75− 90% 5-year 
survival 
6MWD: 6-minute walking distance, BPA: Balloon Pulmonary Angioplasty, PEA: 
Pulmonary Endarterectomy, PVR: Pulmonary Vascular Resistance, RCT: Ran-
domized Controlled Trial. 
Table 2 































68 213 42.9 25 12.5 5.8 349 ± 130–424 ±
111 
98.5% at 2 yrs. 1.47 % 
Inami, 2014 
[73] 
103 350 41 21 8.7 2.7 360 to 420 NR 0.97 % 
Shimura, 
2015 [86] 





97 500 45.1 ± 10.8 23.3 ± 6.4 12 ± 5.7 3.9 ± 1.9 276.3 ± 123.2 
359.3 ± 91.9 
NR 4% 





56 266 40 ± 12 33 ± 11 7.4 ± 3.6 5.5 ± 3.5 358 ± 108–391 ±
108 
NR 1.8 % 
Kurzyna, 2017 
[74] 
56 157 50.7 ± 10.8 35.6 ± 9.3 10.3 ± 3.7 5.9 ± 2.8 306 ± 153–397 ±
123 





308 1408 43.2 ± 11 24.3 ± 6.4 10.7 ± 5.6 4.5 ± 2.8 318.1 ±
122.1–401.3 ±
104.8 
96.8% at 1–2 yrs. 
94.5% at 3 yrs. 
2.6 % 
Aoki, 2017 [58] 77 424* (no of 
pts:84) 
38 ± 10 25 ± 6 7.3 ± 3.2 3.8 ± 1.0 380 ± 138–486 ±
112 
98.4 % at 5 yrs. 0 
Kimura, 2017 
[87] 










184 1006 43.9 ± 9.5 31.6 ± 9.0 7.5 ± 2.8 4.1 ± 2.2 396 ± 120–441 ±
104 
95.1% at 3yrs 3.8 %  
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on the untreated contralateral side in a series of unilateral BPA sessions 
[79]. 
The histological mechanisms by which BPA improves hemodynamics 
are still being studied; few case reports available from pathological 
specimens suggest arterial lumen dilation by forcing the organized 
thrombus to one side, whether accompanied by vessel wall dissection 
and partial detachment of lumen thrombus [80], or by incision and 
compression of thrombi without dissection [81]. The former phenome-
non stresses the importance of applying smaller balloons in initial ses-
sions to lower the risk of wall injury and complications. Another study 
analyzed the occlusive lesions using gray-scale and virtual histology 
(VH) intravascular ultrasound (IVUS) pre-and post-BPA, which revealed 
an increment in lumen area without expanding the total vessel area. The 
IVUS-VH technique has the power for in vivo characterization of tissue 
composition and derived color-coded images suggest variable suscepti-
bility of the organized thrombus to imposed mechanical compression. 
Therefore, it helps evaluate lesion vulnerability to the applied 
compression and potentially predict the expected BPA effect [82]. 
Maruoka et al. investigated the applicability of three-dimensional 
fractal analysis using 99mTc-MAA SPECT pulmonary perfusion scintig-
raphy as a non-invasive tool for assessment of BPA results in CTEPH 
patients. The increased uptake volume in both lungs and lesser hetero-
geneity on SPECT images were associated with the lower mPAP in 
CTEPH patients. In post-BPA SPECT, they found fractal analysis to be 
discriminative between BPA success and failure with 75 % sensitivity, 79 
% specificity, 78 % accuracy, and an area under the receiver operating 
characteristic curve of 0.85 [83]. 
With the evolution of BPA and its growing application, novel tech-
niques and devices are being innovated to predict BPA outcomes before 
and after the procedure, diminish complication rates and eventually 
amend results. In this regard, Miyazaki et al. invented a radiation pro-
tection sheet supported by an acrylic table to minimize radiation 
exposure of the operator and medical staff during BPA procedures [84]. 
12. Conclusion 
On the road to establishing a standard therapy option, the BPA 
technique should be unified worldwide. Expert CTEPH centers with all 
treatment options available on-site should be designated, and proper 
training programs be designed. The most suitable therapeutic option for 
each patient should be determined by multidisciplinary discussion to 
reduce the complication rates and maximize patient benefits. While PEA 
remains the preferred therapy, BPA, with its promising results, brings 
bright horizons ahead. 
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